PHB2 and breast carcinoma: The most notable aspects of this therapeutic strategy are that (1) PHB2 reactivated by ERAP suppresses various E2-ERα signaling networks, which are responsible for resistance to endocrine therapy, and (2) ERAP has antitumor effect on endocrine-resistant breast cancer xenografts [89].